Ikarian Capital
Overview
Ikarian Capital is a long/short equity hedge fund manager focused on the therapeutics and biotechnology sub-sectors. The firm employs a long/short investment strategy, seeking investment opportunities in public and private markets. They aim to generate high, risk-adjusted returns uncorrelated to the broader market, primarily through a fundamental approach to identify investment opportunities in the biotechnology and pharmaceutical sub-sectors. The Adviser seeks to construct a portfolio of high conviction ideas with asymmetric risk/reward payoffs.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| NexCure, Inc. | Nov 2025 | Private Placement | Lead |
| Immusoft | Sep 2020 | Series B | Co-investor |
| Jasper Therapeutics | Jul 2026 | PIPE | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Ikarian Capital based?
Ikarian Capital is headquartered in Dallas, Texas, United States.
When was Ikarian Capital founded?
Ikarian Capital was founded in 2015.
How many portfolio companies does Ikarian Capital have?
Ikarian Capital has 3 portfolio companies in Caplight's dataset.
What are some companies in Ikarian Capital's portfolio?
Portfolio companies visible on Caplight include NexCure, Inc., Immusoft, Jasper Therapeutics.
What was Ikarian Capital's most recent investment shown here?
Ikarian Capital's most recent investment in this portfolio sample was in Jasper Therapeutics in 2026.
What sectors does Ikarian Capital focus on?
Ikarian Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Ikarian Capital focus on?
Stage focus information for Ikarian Capital is not publicly available.